We are translating our understanding of the biology underlying retinal diseases to develop much‑needed therapies.
Today, people suffering from diabetic retinopathy, diabetic macular edema and wet age-related macular degeneration have very limited treatment options. With the currently available treatments, which use an anti-VEGF mechanism, a large proportion of patients still end up with significant visual impairment and administration of these treatments proves challenging for many.
We are seeking to uncover the pathology of these conditions, identify targets for therapy and bring treatments to people in need, which improve visual acuity and prevent the complete loss of vision. To do this, we are leveraging our existing expertise in immunology, vascular disease and neuroscience and collaborating with leading research communities to fully explore the underlying biology of retinal diseases.